Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, Weroha SJ, Jen J, Sarkaria JN, Galanis E.

J Natl Cancer Inst. 2018 May 16. doi: 10.1093/jnci/djy033. [Epub ahead of print]

PMID:
29788332
2.

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.

Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirer GG, Satele D, Allred J, Lensing JL, Chen A, Ji J, Zang Y, Erlichman C, Haluska P, Kaufmann SH.

Clin Cancer Res. 2018 Feb 15;24(4):744-752. doi: 10.1158/1078-0432.CCR-17-1590. Epub 2017 Nov 14.

PMID:
29138343
3.

Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts.

Butler KA, Hou X, Becker MA, Zanfagnin V, Enderica-Gonzalez S, Visscher D, Kalli KR, Tienchaianada P, Haluska P, Weroha SJ.

Neoplasia. 2017 Aug;19(8):628-636. doi: 10.1016/j.neo.2017.04.007. Epub 2017 Jun 26.

4.

Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.

Colon-Otero G, Weroha SJ, Foster NR, Haluska P, Hou X, Wahner-Hendrickson AE, Jatoi A, Block MS, Dinh TA, Robertson MW, Copland JA.

Gynecol Oncol. 2017 Jul;146(1):64-68. doi: 10.1016/j.ygyno.2017.04.020. Epub 2017 Apr 28.

PMID:
28461031
5.

Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.

Earp MA, Raghavan R, Li Q, Dai J, Winham SJ, Cunningham JM, Natanzon Y, Kalli KR, Hou X, Weroha SJ, Haluska P, Lawrenson K, Gayther SA, Wang C, Goode EL, Fridley BL.

Oncotarget. 2017 Jul 18;8(29):46891-46899. doi: 10.18632/oncotarget.16781.

6.

Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.

Andersen CL, Sikora MJ, Boisen MM, Ma T, Christie A, Tseng G, Park Y, Luthra S, Chandran U, Haluska P, Mantia-Smaldone GM, Odunsi K, McLean K, Lee AV, Elishaev E, Edwards RP, Oesterreich S.

Clin Cancer Res. 2017 Jul 15;23(14):3802-3812. doi: 10.1158/1078-0432.CCR-16-1501. Epub 2017 Jan 10.

7.

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.

Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.

8.

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.

Becker MA, Hou X, Tienchaianada P, Haines BB, Harrington SC, Weroha SJ, Sathyanarayanan S, Haluska P.

BMC Cancer. 2016 Oct 20;16(1):814.

9.

High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome.

Delgado E, Boisen MM, Laskey R, Chen R, Song C, Sallit J, Yochum ZA, Andersen CL, Sikora MJ, Wagner J, Safe S, Elishaev E, Lee A, Edwards RP, Haluska P, Tseng G, Schurdak M, Oesterreich S.

Gynecol Oncol. 2016 May;141(2):348-356. doi: 10.1016/j.ygyno.2016.02.030. Epub 2016 Mar 11.

10.

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, Beeram M, Molina JR, Rasco DW, Arcos RR, Kelly CS, Wijayawardana SR, Zhang X, Stancato LF, Bell R, Shi P, Kulanthaivel P, Pitou C, Mulle LB, Farrington DL, Chan EM, Goetz MP.

Clin Cancer Res. 2016 Mar 1;22(5):1095-102. doi: 10.1158/1078-0432.CCR-15-1718. Epub 2015 Nov 18. Erratum in: Clin Cancer Res. 2016 May 15;22(10 ):2596.

11.

Molecular and clinical implementations of ovarian cancer mouse avatar models.

Zayed AA, Mandrekar SJ, Haluska P.

Chin Clin Oncol. 2015 Sep;4(3):30. doi: 10.3978/j.issn.2304-3865.2015.04.01. Review.

12.

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.

Gradishar WJ, Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, Schwartz GN, Youssoufian H, Tang S, Novosiadly R, Forest A, Nguyen TS, Cosaert J, Grebennik D, Haluska P.

Clin Cancer Res. 2016 Jan 15;22(2):301-9. doi: 10.1158/1078-0432.CCR-15-0588. Epub 2015 Aug 31.

13.

Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment.

Lodhia KA, Tienchaiananda P, Haluska P.

Front Oncol. 2015 Jul 8;5:142. doi: 10.3389/fonc.2015.00142. eCollection 2015. Review.

14.

Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.

Glaser G, Weroha SJ, Becker MA, Hou X, Enderica-Gonzalez S, Harrington SC, Haluska P.

PLoS One. 2015 May 11;10(5):e0126867. doi: 10.1371/journal.pone.0126867. eCollection 2015.

15.

Prioritizing therapeutic targets using patient-derived xenograft models.

Lodhia KA, Hadley AM, Haluska P, Scott CL.

Biochim Biophys Acta. 2015 Apr;1855(2):223-34. doi: 10.1016/j.bbcan.2015.03.002. Epub 2015 Mar 14. Review.

16.

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.

Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC; Translational Breast Cancer Research Consortium (TBCRC).

Clin Cancer Res. 2015 Jun 15;21(12):2722-9. doi: 10.1158/1078-0432.CCR-14-2780. Epub 2015 Mar 16.

17.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.

18.

A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.

Becker MA, Haluska P Jr, Bale LK, Oxvig C, Conover CA.

Mol Cancer Ther. 2015 Apr;14(4):973-81. doi: 10.1158/1535-7163.MCT-14-0880. Epub 2015 Feb 18.

19.

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC.

Cancer Res. 2015 Jan 1;75(1):22-30. doi: 10.1158/0008-5472.CAN-14-2533. Epub 2014 Nov 14.

20.

Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies.

Reid JM, Goetz MP, Buhrow SA, Walden C, Safgren SL, Kuffel MJ, Reinicke KE, Suman V, Haluska P, Hou X, Ames MM.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1271-8. doi: 10.1007/s00280-014-2605-7. Epub 2014 Oct 16.

21.

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE.

Br J Cancer. 2014 Nov 11;111(10):1932-44. doi: 10.1038/bjc.2014.497. Epub 2014 Oct 7.

22.

Can we unlock the potential of IGF-1R inhibition in cancer therapy?

King H, Aleksic T, Haluska P, Macaulay VM.

Cancer Treat Rev. 2014 Oct;40(9):1096-105. doi: 10.1016/j.ctrv.2014.07.004. Epub 2014 Aug 4. Review.

23.

Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.

Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P.

Clin Cancer Res. 2014 Sep 15;20(18):4747-57. doi: 10.1158/1078-0432.CCR-14-0114. Epub 2014 Jul 14. Erratum in: Clin Cancer Res. 2014 Dec 1;20(23):6224. Huang, Jaiqi [corrected to Huang, Jiaqi].

24.

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP.

Gynecol Oncol. 2014 Sep;134(3):478-85. doi: 10.1016/j.ygyno.2014.06.029. Epub 2014 Jul 10.

25.

Patient-derived xenograft models in gynecologic malignancies.

Scott CL, Mackay HJ, Haluska P Jr.

Am Soc Clin Oncol Educ Book. 2014:e258-66. doi: 10.14694/EdBook_AM.2014.34.e258. Review.

26.

North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.

Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, Watanaboonyakhet P, Weiss M, Adams PT, Dockter TJ, Loprinzi CL; Alliance for Clinical Trials in Oncology.

Cancer. 2014 Jun 15;120(12):1890-7. doi: 10.1002/cncr.28654. Epub 2014 Mar 11.

27.

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P.

Clin Cancer Res. 2014 Mar 1;20(5):1288-97. doi: 10.1158/1078-0432.CCR-13-2611. Epub 2014 Jan 7.

28.

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.

Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R.

Cancer Chemother Pharmacol. 2014 Mar;73(3):467-73. doi: 10.1007/s00280-013-2372-x. Epub 2014 Jan 4.

PMID:
24390424
29.

Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.

Scott CL, Becker MA, Haluska P, Samimi G.

Front Oncol. 2013 Dec 4;3:295. doi: 10.3389/fonc.2013.00295. Review.

30.

Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.

Becker MA, Farzan T, Harrington SC, Krempski JW, Weroha SJ, Hou X, Kalli KR, Wong TW, Haluska P.

Mol Cancer Ther. 2013 Dec;12(12):2909-16. doi: 10.1158/1535-7163.MCT-13-0547. Epub 2013 Oct 15.

31.

Epithelial ovarian cancer experimental models.

Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS.

Oncogene. 2014 Jul 10;33(28):3619-33. doi: 10.1038/onc.2013.321. Epub 2013 Aug 12. Review.

32.

Two birds with one stone: octreotide treatment for acromegaly and breast cancer.

Chae YK, Hu MI, Katz RL, Chavez-MacGregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A.

J Clin Oncol. 2013 Aug 10;31(23):e398-400. doi: 10.1200/JCO.2012.46.6383. Epub 2013 Jun 24. No abstract available.

33.

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.

Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF.

Breast Cancer Res Treat. 2013 May;139(1):145-53. doi: 10.1007/s10549-013-2528-8. Epub 2013 Apr 19.

34.

Developing safety criteria for introducing new agents into neoadjuvant trials.

DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L.

Clin Cancer Res. 2013 Jun 1;19(11):2817-23. doi: 10.1158/1078-0432.CCR-12-2620. Epub 2013 Mar 7. Review.

35.

Intrathecal metastases causing conus medullaris syndrome.

Liang JJ, Kizilbash SH, Haluska P.

QJM. 2014 Jan;107(1):75. doi: 10.1093/qjmed/hct008. Epub 2013 Jan 21. No abstract available.

PMID:
23340390
36.

Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.

Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L.

J Clin Oncol. 2012 Dec 20;30(36):4584-6; author reply 4588-9. doi: 10.1200/JCO.2012.44.1022. Epub 2012 Nov 19. No abstract available.

PMID:
23169510
37.

Hormone response in ovarian cancer: time to reconsider as a clinical target?

Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P, Oesterreich S.

Endocr Relat Cancer. 2012 Nov 9;19(6):R255-79. doi: 10.1530/ERC-12-0175. Print 2012 Dec. Review.

38.

The insulin-like growth factor system in cancer.

Weroha SJ, Haluska P.

Endocrinol Metab Clin North Am. 2012 Jun;41(2):335-50, vi. doi: 10.1016/j.ecl.2012.04.014. Review.

39.

An organ system based approach to prognosis in advanced melanoma.

Holtan SG, Mansfield AS, Creedon DJ, Nevala WK, Haluska P, Leontovich AA, Markovic SN.

Front Biosci (Elite Ed). 2012 Jun 1;4:2723-33.

PMID:
22652681
40.

Quantifying insulin receptor isoform expression in FFPE breast tumors.

Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P.

Growth Horm IGF Res. 2012 Jun-Aug;22(3-4):108-15. doi: 10.1016/j.ghir.2012.04.001. Epub 2012 Apr 30.

41.

IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.

Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, Carboni JM, Gottardis MM, Haluska P.

Clin Cancer Res. 2012 Mar 15;18(6):1808-17. doi: 10.1158/1078-0432.CCR-11-1806. Epub 2012 Jan 27.

42.

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.

Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P.

Gynecol Oncol. 2012 Feb;124(2):210-5. doi: 10.1016/j.ygyno.2011.10.002. Epub 2011 Nov 1.

43.

Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, Finckenstein FG, Brodie A, Gottardis MM, Carboni JM, Haluska P.

Cancer Res. 2011 Dec 15;71(24):7597-607. doi: 10.1158/0008-5472.CAN-11-1080. Epub 2011 Oct 31.

44.

Recurrent basal cell carcinoma: a clinicopathological study and evaluation of histomorphological findings in primary and recurrent lesions.

Bartoš V, Pokorný D, Zacharová O, Haluska P, Doboszová J, Kullová M, Adamicová K, Péč M, Péč J.

Acta Dermatovenerol Alp Pannonica Adriat. 2011 Jun;20(2):67-75.

45.

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.

O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S.

Cancer Chemother Pharmacol. 2012 Mar;69(3):605-12. doi: 10.1007/s00280-011-1733-6. Epub 2011 Sep 22.

PMID:
21938545
46.

Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.

Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P.

Invest New Drugs. 2012 Oct;30(5):1934-41. doi: 10.1007/s10637-011-9742-1. Epub 2011 Sep 1.

47.

Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.

Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P.

Gynecol Oncol. 2011 Jul;122(1):116-20. doi: 10.1016/j.ygyno.2011.03.030. Epub 2011 Apr 22.

48.

Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.

Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten Eyck C, Nakanishi T, Tibodeau JD, Ross DD, Gottardis MM, Erlichman C, Kaufmann SH, Haluska P.

Mol Cancer Ther. 2011 Jan;10(1):117-25. doi: 10.1158/1535-7163.MCT-10-0438.

49.

Insulin-like growth factor pathway.

Haluska P.

J Thorac Oncol. 2010 Dec;5(12 Suppl 6):S478-9. doi: 10.1097/01.JTO.0000391374.71505.a2. No abstract available.

50.

Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.

Huntoon CJ, Nye MD, Geng L, Peterson KL, Flatten KS, Haluska P, Kaufmann SH, Karnitz LM.

Cancer Res. 2010 Nov 1;70(21):8642-50. doi: 10.1158/0008-5472.CAN-10-1345. Epub 2010 Sep 14.

Supplemental Content

Loading ...
Support Center